Asset Details
Do you wish to reserve the book?
Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy
Do you wish to request the book?
Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy
2020
Overview
Low-grade fibromyxoid sarcoma (LGFMS) is a rare sarcoma subtype with a generally indolent pattern of clinical behaviour, but treatments for advanced disease are limited.
A retrospective search of a prospectively maintained institutional database identified 102 patients treated from December 1994 to August 2018. We evaluated the outcome of patients and the efficacy and safety of non-surgical therapies in LGFMS.
Ninety-four out of 102 (92.2%) underwent primary resection, seven (6.9%) were treated with systemic therapy and one (1.0%) is currently being treated with pre-operative radiotherapy. The RECIST 1.1 response rate to first-line chemotherapy was 0%, and median progression-free survival was 1.84 months (95% confidence intervaI=0.10-3.6 months).
Conventional systemic therapy has limited efficacy in advanced LGFMS.
Publisher
International Institute of Anticancer Research
Subject
